bluuebunny/crossref_metadata_2025_split huggingface dataset:
Pathobiont and symbiont contribute to microbiota homeostasis through Malpighian tubules–gut countercurrent flow in Bactrocera dorsalis
Authors: Liu Yanning , Luo Rengang , Bai Shuai , Lemaitre Bruno , Zhang Hongyu , Li Xiaoxue 
Published: November 2024

Abstract
Host–gut microbiota interactions are more complex than good or bad. Both gut symbiotic bacteria and pathobionts can provide essential functions to their host in one scenario and yet be detrimental to host health in another. So, these gut-dwelling bacteria must be tightly controlled to avoid harmful effects on the host. However, how pathobionts and other symbiotic bacteria coordinate to establish a host immune defense system remains unclear. Here, using a Tephritidae fruit fly Bactrocera dorsalis, we report that both pathobionts and other gut symbiotic bacteria release tyramine, which is recognized by the host insects. These tyramines induce the formation of insect-conserved Malpighian tubules–gut countercurrent flow upon bacterial infection, which requires tyramine receptors and aquaporins. At the same time, pathobionts but not gut symbiotic bacteria induce the generation of reactive oxygen species, which are preserved by the countercurrent flow, promoting bacteria elimination through increasing gut peristalsis. More importantly, our results show that the Malpighian tubules–gut countercurrent flow maintains proper microbiota composition. Our work suggests a model where pathobiont-induced reactive oxygen species are preserved by Malpighian tubules–gut countercurrent flow involving both pathobionts and symbiotic bacteria. Furthermore, our work provides a Malpighian tubules–gut interaction that ensures efficient maintenance of the gut microbiota.
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America
Authors: Ramírez Arianis Tatiana , Mesher David , Baena Armando , Salgado Yuli , Kasamatsu Elena , Cristaldo Carmen , Álvarez Rodrigo , Rojas Freddy David , Ramírez Katherine , Guyot Julieta , Henríquez Odessa , González Palma Hans , Flores Bettsy , Peñaranda Jhaquelin , Vero María José , Robinson Isabel , Rol Mary Luz , Rodríguez Guillermo , Terán Carolina , Ferrera Annabelle , Picconi María Alejandra , Calderon Alejandro , Mendoza Laura , Wiesner Carolina , Almonte Maribel , Herrero Rolando ,   ESTAMPA Study Group, Colucci María Celeste , Reynaga Daysi Colque , Fernández Daniel Llanos , Ortube Omar , Martínez Sandra , González Emmanuel , Guillén Diego , Cabrera Yessy , Mongelós Pamela , Rodríguez María Isabel , Soilán Ana , Ortega Marina , Duarte Elizabeth , García Laura , Caserta Benedicta , Darragh Teresa , Downham Laura 
Published: November 2024

Abstract

Background
Cervical cytology is recommended by the World Health Organization as a triage option in human papillomavirus (HPV)-based cervical cancer screening programs. We assessed the performance of cytology to detect CIN3+ without and with knowledge of HPV positivity.

Methods
Women were screened with cytology and HPV across ESTAMPA study centers in Latin America. Screen-positives were referred to colposcopy with biopsy and treatment as needed. Cytology was initially interpreted without knowing HPV results. A subset of cytologies from HPV-positive women were reinterpreted at the same laboratories, with knowledge of HPV status, blinded to previous cytology and histological diagnosis. Performance indicators for cytology to detect CIN3+ without and with knowledge of HPV positivity were estimated.

Findings
A total of 4087 women were included, of which 490 had histologically confirmed CIN3+ (455 CIN3 and 35 cancers). Cytology sensitivity without knowledge of HPV positivity for CIN3+ was 47.2% (95% CI = 42.5 to 51.9), whereas with knowledge of HPV positivity, the sensitivity was higher (58.9%, 95% CI = 54.2 to 63.5; P &lt; .0001). The specificity without knowledge of HPV was 89.4% (95% CI = 88.2 to 90.5), whereas with knowledge of HPV positivity was 78.9% (95% CI = 77.4 to 80.4; P &lt; .0001). Performance estimates varied by study center for cytology without knowing the HPV positivity (range = 32.8%-61.5% for sensitivity; range = 80.7%-98.6% for specificity). Similarly, performance varied with knowledge of HPV positivity (36.1%-93.4% for sensitivity; 39.6%-98.6% for specificity).

Conclusion
The increase in sensitivity of cytology with HPV knowledge was limited and highly variable, reinforcing the need for alternative triage methods to support cervical cancer elimination goals.
Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study
Authors: Aboumrad Maya , Joshu Corinne , Visvanathan Kala 
Published: November 2024

Abstract

Background
Establishing whether women with major depressive disorder who develop breast cancer have poor outcomes is key to optimizing care for this population. To this end, we examined associations between major depressive disorder and breast cancer recurrence and mortality.

Methods
Using medical record data from the US Department of Veterans Affairs health-care system, we established a retrospective cohort of women with local or regional stage invasive breast cancer between 2010 and 2019 and followed them through 2022. We used a 2-year window to identify women diagnosed with major depressive disorder before breast cancer diagnosis. We used multivariable Cox-proportional hazards regression to estimate associations between major depressive disorder and breast cancer recurrence and mortality while accounting for competing risks and adjusting for sociodemographic, clinical, lifestyle, and tumor characteristics.

Results
We identified 6051 women with breast cancer, of whom 1754 (29%) had major depressive disorder. The mean (SD) age at breast cancer diagnosis was 57 (11) years. In multivariable analyses, women with major depressive disorder had a 37% (hazard ratio = 1.37, 95% CI = 1.19 to 1.57) higher risk of recurrence and a 30% (hazard ratio = 1.30, 95% CI = 1.02 to 1.64) higher risk of breast cancer mortality. The association between major depressive disorder and recurrence was stronger among women with estrogen receptor–positive breast cancer. In secondary analyses, there were statistically significant interactions between major depressive disorder and multiple exposures with respect to recurrence, including current smoking, substance abuse, and nonreceipt of screening mammography.

Conclusions
Women with major depressive disorder had inferior breast cancer outcomes compared with women without a history of major depressive disorder. Research is needed to investigate underlying mechanisms linking depression to breast cancer progression and evaluate interventions to improve outcomes in this high-risk population.
Single-dose human papillomavirus vaccination: an update
Authors: Kreimer Aimée R , Watson-Jones Deborah , Kim Jane J , Dull Peter 
Published: November 2024

Abstract
Human papillomavirus (HPV) vaccines received regulatory approval and were recommended for use in young girls nearly 2 decades ago. Uptake is mostly high in resource-rich settings. In resource-limited settings, where the burden of cervical cancer is disproportionately high, access to and uptake of HPV vaccines are nowhere near satisfactory, despite evidence that HPV vaccination is highly cost-effective and a significant value-for-money investment. The discovery that only a single dose of the HPV vaccines may be needed to confer adequate protection may make equitable access to HPV vaccines possible. Indeed, the recent World Health Organization recommendation allowing for 1 or 2 doses is already gaining traction. This monograph aims to update the state of the science related to single-dose HPV vaccine protection and includes both primary data and modeling efforts that address key gaps in the knowledge regarding 1) durability of protection of a single dose of the HPV vaccine, 2) single-dose HPV vaccine effectiveness in both high-income and low-income settings, 3) implementation of single-dose HPV vaccination, and 4) how to accelerate control of cervical cancer by integrating a 1-time screen for cervical disease. The content published in this monograph will continue to advance the science of HPV vaccination and will be vital as new countries make informed decisions about how best to use this remarkable vaccine.
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
Authors: Porras Carolina , Romero Byron , Kemp Troy , Fantin Romain , Herrero Rolando , Hildesheim Allan , Ocampo Rebeca , Sierra Mónica S , Gail Mitchell H , Schussler John , Schiller John T , Lowy Douglas R , Pinto Ligia A , Liu Danping , Kreimer Aimée R ,   Costa Rica HPV Vaccine Trial Study Group, Cortés Bernal , González Paula , Herrero Rolando , Jiménez Silvia E , Porras Carolina , Rodríguez Ana Cecilia , Hildesheim Allan , Kreimer Aimée R , Lowy Douglas R , Schiffman Mark , Schiller John T , Sherman Mark , Wacholder Sholom , Pinto Ligia A , Kemp Troy J , Sidawy Mary K , Quint Wim , van Doorn Leen-Jan , Struijk Linda , Palefsky Joel M , Darragh Teresa M , Stoler Mark H 
Published: November 2024

Abstract

Background
The Costa Rica HPV Vaccine Trial provided initial evidence that 1 dose of the bivalent human papillomavirus (HPV) vaccine induces stabilizing antibody levels that may provide extended protection against HPV-16/18 infections. We report antibody seropositivity and stability 11 to 16 years after vaccination.

Methods
We invited a random subset of Costa Rica HPV Vaccine Trial participants (n = 398) who had received 3 doses and all women (n = 203) who had received 1 dose at 18 to 25 years of age to follow-up visits 11, 14, and 16 years after vaccination. We calculated HPV-16 and HPV-18 seropositivity and assessed change in enzyme-linked immunosorbent assay antibody levels 11 to 16 years after vaccination among 500 participants.

Results
By year 16, 99.4% (95% confidence interval [CI] = 96.8% to 100.0%) and 100.0% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-16 seropositive and 98.8% (95% CI = 95.9% to 99.9%) and 100% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-18 seropositive. Between years 11 and 16, women who had received 3 doses had a small but statistically significant decrease in the geometric mean concentration for HPV-16 of ‒12.4% (95% CI = ‒16.3% to ‒8.4%) and HPV-18 of ‒13.4% (95% CI = ‒17.2% to ‒9.4%). Among women who had received 1 dose, the decrease was statistically significant for HPV-16 at ‒8.9 (95% CI = ‒14.2% to ‒3.1%) but nonsignificant for HPV-18. Geometric mean concentration ratios of 3:1 dose (year 16) were 3.0 and 2.2 for HPV-16 and HPV-18, respectively.

Conclusions
HPV-16/18 seropositivity remained exceedingly high 16 years after vaccination. Over 5 years, small declines in antibodies were observed. Women should have protection for at least 20 years and likely much longer at the observed rate of decline.
Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling
Authors: Brisson Marc , Laprise Jean-François , Drolet Mélanie , Chamberland Éléonore , Bénard Élodie , Burger Emily A , Jit Mark , Kim Jane J , Markowitz Lauri E , Sauvageau Chantal , Sy Stephen 
Published: November 2024

Abstract

Background
A concern in high-income countries is that switching to 1-dose human papillomavirus (HPV) vaccination could cause a rebound in HPV infection and cervical cancer if 1-dose efficacy or duration were inferior to 2 doses. Using mathematical modeling and up-to-date trial-based data, we projected the population-level effectiveness of switching from 2-dose to 1-dose vaccination under different vaccine efficacy and duration assumptions in high-income countries.

Methods
We used HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation), a transmission-dynamic model of HPV infection and cervical cancer, varying key model assumptions to identify those with the greatest impact on projections of HPV-16 and cervical cancer incidence over time: 1) 1-dose vaccine efficacy and vaccine duration, 2) mechanisms of vaccine efficacy and duration over time, 3) midadult (&gt;30 years of age) sexual behavior, 4) progression to cervical cancer among midadults, and 5) vaccination coverage and programs.

Results
In high-income countries, 1-dose vaccination would cause no appreciable rebound in HPV-16 infection, except for a limited rebound under the most pessimistic assumptions of vaccine duration (average, 25 years), because 1) the switch would occur when HPV prevalence is low because of high 2-dose vaccination coverage and 2) individuals would be protected during their peak ages of sexual activity (&lt;35 to 40 years of age). Our model projects a more limited rebound in cervical cancer because of a shift to older age at infection, resulting in fewer life-years left to potentially develop cancer. Projections were robust when varying key model assumptions.

Conclusions
High protection during peak ages of sexual activity in high-income countries would likely mitigate any potential rebounds in HPV infection and cervical cancer under the most pessimistic assumptions of 1-dose efficacy and duration.
A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination
Authors: Campos Nicole G , Lowy Douglas R , de Sanjosé Silvia , Schiffman Mark 
Published: November 2024

Abstract
One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited “one screen” campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if “one dose, one screen” is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.
De-Med—a tool to identify and classify potentially inappropriate medication according to Beers criteria, STOPP, and FORTA: a cross-sectional study
Authors: Syed Jehath , Verma Auroshree , Chopra Vansh , Khemchandani Vineeta , Pereira Prathiba , Patil Vikram , Ramesh Madhan , Chalasani Sri Harsha 
Published: November 2024

Abstract

Objective
A significant number of older adults are affected by the use of potentially inappropriate medications (PIMs), leading to various adverse outcomes, such as increased physical and cognitive impairment, frailty, hospitalization, and mortality. The objective of this study was to develop and test the reliability and feasibility of the De-Med tool.

Methods
This tool was developed using ReactJS for data extraction and manipulation. Users can upload drug lists for analysis, and the software delineates PIMs adhering to the Beers 2019 version, Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) Version 2, and Fit fOR The Aged (FORTA) 2021 criteria. Reliability was assessed by juxtaposing software-generated outputs with manual assessments conducted by independent research pharmacists using retrospective medication records. The System Usability Scale (SUS) and AttrakDiff Mini questionnaires were used to assess feasibility and usability, respectively.

Key findings
Manual and software-generated PIM identifications agreed completely, demonstrating high reliability (100% concordance). A total of 1496 PIMs were identified from 231 records, with an average of 0.63 encounters per patient. The overall usability score was 83.75, indicating “Excellent.” According to the AttrakDiff ratings, users attributed the software to both pragmatic (mean PQ:1.84) and hedonic (mean HQ:1.50) qualities, with moderate overall attractiveness (mean ATT:2.13).

Conclusions
This web-based tool successfully identified PIMs with perfect reliability, high usability, and a moderate level of attractiveness. This tool has the potential to improve medication management in older adults by reducing PIMs.
Angiostrongylus cantonensis Meningoencephalitis in Three Pediatric Patients in Florida, USA
Authors: Chance Melinda D , Noel Anniesha D , Thompson Amelia B , Marrero Natalie , Bula-Rudas Fernando , Horvat Christopher M , Green Jerril , Armstrong Jennifer E , Levent Fatma , Dudas Robert A , Shaffren Serena , Samide Aaron , Martinez Katie , Stockdale Kimberly , Chancey Rebecca J 
Published: November 2024

Abstract
Eosinophilic meningoencephalitis caused by Angiostrongylus cantonensis has been reported in several southern U.S. states and Hawai‘i. We present the first locally acquired human cases of A. cantonensis meningoencephalitis in three children in Florida, occurring between June 2021 and January 2022. Clinicians should be attuned to this possible diagnosis in this region.
Feasibility of creating a daily adaptive plan using automatic DIR-created target and OARs contours in patients with prostate cancer magnetic-resonance-guided adaptive radiotherapy
Authors: Saito Makoto , Abe Kota , Tsuneda Masato , Fujita Yukio , Abe Yukinao , Nishimura Tsumugi , Kodate Asuka , Kanazawa Aki , Harada Rintaro , Watanabe Miho , Uno Takashi 
Published: November 2024

Abstract
The purpose of this study was to evaluate the feasibility of treatment plans for prostate cancer with magnetic resonance (MR)-guided online adaptive radiotherapy, which are generated using deformable image registration (DIR)-created contours of the targets and organs. Totally, 150 fractions from 30 prostate cancer patients implanted with a hydrogel spacer and treated with the MR-Linac were studied. Reference treatment plans that satisfied all institutional dose constraints were initially created on planning MRI. The adaptive treatment plans were created on daily MRI based on the reference plan using the DIR-created contours, ensuring all dose constraints were met. Subsequently, a clinician manually created reference contours for each daily MRI. Finally, the dose volume histogram indices of the plan generated with DIR-created contours were re-evaluated with clinician created contours. The evaluated contours included the bladder wall, rectum wall, sigmoid, small bowel and planning target volume (PTV) for dose prescription. The PTV for dose prescription met the dose constraints in all fractions. The bladder and rectum walls met the dose constraint of maximum dose (D0.03 cc) in all fractions. Five patients failed to meet the sigmoid and small bowel dose constraints, with the largest deviation being 13.3% exceedance at D2 cc in the small bowel added 3 mm margin. This study suggests that most treatment plans created without modifying the DIR-created contours are clinically viable. However, dislodgements of the small bowel and sigmoid may exceed the extent of DIR propagation from the reference plan contours, and it is recommended that these contours be verified.
The Paradoxical Development of Liberal Governance: International Adoption Policy and Professional Social Work in Authoritarian South Korea, 1953–1976
Authors: Koo Youngeun 
Published: November 2024

Abstract
This article explores the development of international adoption policy in post-liberation South Korea, emphasizing the roles of American and Korean professional social workers. By analyzing the orphan registry and a pivotal international adoption law, it reveals how international adoption in South Korea presents a unique opportunity to observe the formation of modern social policy in a newly liberated nation during the Cold War. The study argues that adoption policy served as a crucial locus of transnational governance, where American and Korean social workers pursued their liberal ideals of professional social work within the context of the authoritarian policies of the South Korean state. However, their quest for scientific professionalism, standardized procedures, and public oversight led to a paradoxical evolution of adoption policy, diverging sharply from the trajectory seen in Western liberal democracies where social work significantly contributed to the consolidation and expansion of the welfare state. In South Korea, embedded transnationality and ideological mismatch resulted in the state’s further withdrawal and the creation of policy workarounds that undermined the core social work principle of the child’s best interests. This case highlights the complexities and blurred moral boundaries in the shaping of modern governance and the broader journey toward modernity under postcolonial, Cold War conditions.
Predictors of corporo-venocclusive dysfunction in men with bilateral nerve-sparing radical prostatectomy
Authors: Flores Jose M , Novaes Luis F , Vertosick Emily , Salter Carolyn , Liso Nicole , Vickers Andrew J , Mulhall John P , FECSM  
Published: November 2024

Abstract

Background
Erectile dysfunction (ED) is seen in some men who have undergone bilateral nerve-sparing surgery. Corporo-venocclusive dysfunction (CVOD) is the major pathway to permanent ED after radical prostatectomy (RP).

Aim
To identify comorbidity factors that are associated with the presence of CVOD in men who had undergone bilateral nerve-sparing RP.

Methods
We included patients who had no ED before RP, underwent bilateral nerve-sparing RP, were unresponsive to pharmacotherapy, and had a penile Duplex Doppler Ultrasound (PDDU) with a diagnosis of CVOD. PDDU was performed with a redosing vasoactive agent protocol. A logistic regression model was created to define predictors of CVOD, defined as end-diastolic velocity (EDV) ≥ 5 cm/s bilaterally.

Outcomes
CVOD diagnosis.

Results
135 patients with a median age of 60 (IQR 54, 64) years were included. 45% reported ≥2 comorbidities, 10% diabetes, 28% obstructive sleep apnea (OSA), and 44% were current or former smokers. At PDDU, 34% had less than penetration hardness erections, and 43% received 100 units of vasoactive agent. 44% were diagnosed with CVOD. Increased age at RP (OR 2.12 per 10 years, 95% CI 2.35, 3.73, P = .007) and OSA (OR 2.44, 95% CI 1.07, 5.73, P = .036) were associated with a diagnosis of CVOD.

Clinical implications
Comorbidities, especially OSA, have a role in erection recovery after surgery.

Strengths and limitations
The study used a well-established institutional RP nerve-sparing score, a strict PDDU vasoactive agent redosing protocol, validated cut-offs for CVOD diagnosis, and a validated erectile function questionnaire both pre- and post-operatively. The major limitation is that this is a cohort of men seeking treatment at a sexual medicine clinic for post-operative ED, which limits the generalizability of the results to patients without ED symptoms or who decided not to seek treatment. The dichotomous definition of comorbidities is also a limitation since patients can have differing degrees of comorbidities’ severity.

Conclusion
Older patients and the presence of OSA were associated with the presence of CVOD.